Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Cross-sectional Study of Sarcopenia in Patients With Parkinson ' s Disease

Authors not listed

Second Affiliated Hospital, Zhejiang University, School of Medicine · 2021

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease of aging. The average age of PD onset is about 60 years old. Sarcopenia is common in PD patients, and one in five Parkinson's patients is diagnosed with severe sarcopenia. The prevalence of Parkinson's disease is expected to increase in the coming decades as the population ages. Sarcopenia is a syndrome with progressive and widespread loss of skeletal muscle mass and function, resulting in disability, loss of quality of life, and even death. Chronic disease, long-term bedridden, unreasonable diet and drug therapy may be the important factors leading to sarcopenia. China is gradually stepping into an aging society. Sarcopenia, as an age-related disease, lacks effective treatment, and has become a global public health problem and frontier research problem, bringing huge economic burden to families and society. The decline of the musculoskeletal system in the elderly will lead to muscle atrophy and loss of muscle strength, as well as decreased motor ability and balance ability, and ultimately lead to a decline in the quality of life of the elderly. The European Working Group on Sarcopenia recommends routine screening for sarcopenia in older people aged 65 and over in the community. At present, screening for sarcopenia has not received enough attention in China, and there is no unified standard for screening methods. The assessment of sarcopenia mainly focuses on three aspects: muscle mass, muscle strength and muscle function. The main symptoms of Parkinson's disease patients are postural tremor, bradykinesia and stiffness. The existence of sarcopenia may lead to poor treatment control in PD patients, and the recognition of sarcopenia in PD patients may have therapeutic effects. This project through the cross-sectional survey of Parkinson's disease less muscle disease prevalence situation, further clear according to Parkinson's disease staging classification muscle disease prevalence, less and less by Logistic regression analysis to investigate the muscle disease and Parkinson's disease progression and the correlation between the severity of disease, for the next step nursing intervention strategies for implementation of PD patients less muscle disease provides guidance basis, to prevent and delay the less muscle disease is of great significance.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-23 MST

Cite this

APA
Anonymous. (2021). A Cross-sectional Study of Sarcopenia in Patients With Parkinson ' s Disease. <em>Second Affiliated Hospital, Zhejiang University, School of Medicine</em>. https://clinicaltrials.gov/study/NCT04721028
Vancouver
Anonymous. A Cross-sectional Study of Sarcopenia in Patients With Parkinson ' s Disease. Second Affiliated Hospital, Zhejiang University, School of Medicine. 2021.
BibTeX
@misc{anon2021ACross, title = {A Cross-sectional Study of Sarcopenia in Patients With Parkinson ' s Disease}, author = {Anonymous}, journal = {Second Affiliated Hospital, Zhejiang University, School of Medicine}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings